Regulatory Update — Week of June 3, 2024 Post author:PacConAdmin Post published:June 7, 2024 Post category:Uncategorized This week, the FDA issued two draft guidances on Bioresearch Monitoring Inspections (BIMO). Source: Drug Industry Daily Tags: aaps Read more articles Previous PostBiomea Fusion Diabetes Drug Clinical Trials Placed on FDA Hold Next PostAdComm Will Tussle With Donanemab’s High ARIA Rate in June 10 Meeting You Might Also Like Adcomm Agrees With FDA, Votes Down Intarcia’s T2 Diabetes Combo Product September 22, 2023 Biologic Manufacturer Fails to Test for Diseases, Gets FDA Warning Letter May 22, 2024 Regulatory Update — Week of Dec. 11, 2023 December 15, 2023